Drugs targeting AngII action or production, such as angiotensin-converting enzyme (ACE) inhibitors and AngII receptor blockers (ARB), have a protective effect in diabetic and non-diabetic nephropathies, since they can reduce proteinuria and the rate of loss of renal function, and reduce cardiovascular risk in CKD patients [71]. This evidence concerns the gene ACE and Nephropathy.